Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR). Issue 4 (2000)

• Record Type: Journal Article
• Authors: Marcon Marcon, G. G.; Casini Casini, A. A.; Mura Mura, P. P.; Messori Messori, L. L.; Bergamo Bergamo, A. A.; Orioli Orioli, P. P.
• Is Part Of: Metal-based drugs. Volume 7:Issue 4(2000)
• Page Start: 195
• Page End: 200
• Publication Date: 2000
• Subjects: Metals -- Therapeutic use -- Periodicals; Pharmaceutical chemistry -- Periodicals; Drugs -- Periodicals; Drugs; Metals -- Therapeutic use; Pharmaceutical chemistry; Chemistry, Pharmaceutical -- Periodicals; Metals -- therapeutic use -- Periodicals; Pharmaceutical Preparations -- Periodicals; Periodicals; Electronic journals; 615.23
• DOI: 10.1155/MBD.2000.195
• Languages: English
• ISSNs: 0793-0291

Abstract

Abstract : Some biological aspects of the new complex imidazolium bisimidazole tetrachloro iridate(III)-IRIM- the iridium(III) analogue of ICR, were considered. More in detail the conformational effects produced by IRIM on DNA and the cytotoxic properties of IRIM on some selected human cell lines were measured. Dialysis experiments and DNA thermal denaturation studies are suggestive of poor binding of IRIM to DNA; formation of interstrand crosslinks is not observed. In any case CD measurements suggest that addition of increasing amounts of IRIM to calf thymus DNA results into significant spectral changes, that are diagnostic of a direct interaction with DNA. A number of experiments carried out on the A2780 human ovarian carcinoma, B16 murine melanoma, MCF7 and TS mammary adenocarcinoma tumor cell lines strongly point out that IRIM does not exhibit significant growth inhibition effects within the concentration range 10 -4 -10 -6 M. It is suggested that the lower biological effects of IRIM compared to ICR are a consequence of the larger kinetic inertness of the iridium(III) center with respect to ruthenium(III).